[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Changzhi People's Hospital Affiliated to Changzhi Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,66,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100598311","the-construction-of-a-predictive-model-for-gastric-cancer-immunotherapy-response-based-on-tumor-infiltrating-lymphocytes-tils-and-histone-h3k4me3-in-the-tumor-microenvironment-100598311",false,"NCT07069842","The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment","Inclusion Criteria:\n\n* 1.Diagnosed with histologically confirmed locally advanced (LA) unresectable or metastatic gastric\u002Fgastroesophageal junction (G\u002FGEJ) adenocarcinoma, aged 18 to 75 years.\n\n  2.Scheduled to receive first-line therapy with ICIs plus chemotherapy with or without anti-her-2 therapy.\n\n  3.Have at least one measurable lesion as the target lesion per iRECIST V.1.1 criteria and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n\\- 1.History of secondary malignant tumors within 3 years prior to study initiation, or other types of brain\u002Fmeningeal metastatic tumors.\n\n2.Presence of concomitant diseases that, in the investigator's judgment, may seriously jeopardize their safety or interfere with study completion","ALL","18 Years","75 Years",{"count":19,"type":20},170,"ESTIMATED","1 Year","OBSERVATIONAL","Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved. The emergence of immunotherapy has broken through the bottleneck of chemotherapy for gastric cancer. However, the therapeutic efficacy of immunotherapy varies significantly among patients and still needs to be enhanced. Extensive research has demonstrated that the efficacy of immunotherapy for gastric cancer is significantly influenced by the tumor microenvironment (TME) and epigenetic modifications. The dynamic changes in tumor-infiltrating lymphocytes (TILs) and histone H3K4me3 may reshape the TME, thereby affecting the efficacy of immunotherapy. Based on these findings, this study proposes the scientific hypothesis that the density and spatial distribution of TILs in the TME, as well as the level of H3K4me3 modification, may serve as key biomarkers for predicting the response of gastric cancer patients to immunotherapy. This project aims to delve into the potential mechanisms by which TILs and H3K4me3 enhance the efficacy of immune checkpoint inhibitors (ICIs) and to construct a predictive model for the response to immunotherapy in gastric cancer based on TILs and H3K4me3. The establishment of this model will help identify the patient population most likely to benefit from immunotherapy, facilitate personalized treatment, provide new ideas and approaches for the treatment of gastric cancer, and advance the field of gastric cancer immunotherapy.",[25,26],"Gastric Cancer","Immunotherapy","RECRUITING","2025-07-07",{"date":30,"type":31},"2025-07-17","ACTUAL",{"date":33,"type":31},"2025-01-01",{"date":35,"type":20},"2026-12-31",{"name":37,"class":38},"Changzhi People's Hospital Affiliated to Changzhi Medical College","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100555401","the-anti-reflux-effect-of-double-flap-technique-in-laparoscopic-proximal-gastrectomy-100555401","NCT06511609","The Anti-reflux Effect of Double-flap Technique in Laparoscopic Proximal Gastrectomy.","Comparison of Anti-reflux Effects of Laparoscopic Proximal Gastrectomy With Double-flap Technique (Kamikawa Anastomosis) Versus Double-tract Reconstruction: A Prospective, Multicenter, Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Age between 20 and 80 years, regardless of gender;\n2. Patients diagnosed with gastric cancer through tissue biopsy;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n4. American Society of Anesthesiologists (ASA) classification of I to III;\n5. Acceptable for laparoscopic proximal gastrectomy with preoperative examinations (based on endoscopic ultrasound and\u002For contrast-enhanced computed tomography of the thorax and abdomen) confirming the following oncological features:\n\n   Primary tumor located in the upper part of the stomach (proximal 1\u002F3 of the stomach) or gastroesophageal junction; Length of esophageal invasion ≤ 1 cm, tumor maximum diameter ≤ 4 cm; Preoperative staging T1-3N0M0 (based on AJCC 8th edition TNM clinical staging);\n6. Voluntary signing of informed consent.\n\nExclusion Criteria:\n\n1. Received preoperative chemotherapy, radiotherapy, targeted therapy, or immunotherapy;\n2. Presence of contraindications to surgery;\n3. Multiple malignant lesions in the stomach;\n4. Presence of other malignancies that may affect the preservation of stomach function;\n5. Previous upper abdominal surgery (excluding cholecystectomy);\n6. Preoperative examination reveals active peptic ulcer;\n7. Patients who have received or are currently receiving treatment for systemic inflammatory diseases;\n8. Pregnant or breastfeeding women;\n9. Conditions deemed unsuitable for participation in this study by the investigator.","20 Years","80 Years",{"count":50,"type":20},244,"INTERVENTIONAL",[53],"NA","This study is a multicenter, open-label, prospective, randomized parallel-controlled trial. The purpose is to explore whether the incidence rate of reflux esophagitis (RE) within 12 months after surgery is non-inferior for the DFT group compared to the DTR group.",[56],"Proximal Early Gastric Cancer","NOT_YET_RECRUITING","2024-07-15",{"date":60,"type":31},"2024-07-22",{"date":62,"type":20},"2024-08-01",{"date":64,"type":20},"2027-07-31",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":39},"100553375","a-real-world-study-of-camrelizumab-alone-or-in-combination-with-apatinibchemotherapy-for-advanced-gastric-cancer-100553375","NCT06485271","A Real-world Study of Camrelizumab Alone or in Combination With Apatinib\u002FChemotherapy for Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age ≥18 years old, both male and female;\n2. patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;\n3. Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;\n4. The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;\n5. Voluntary enrollment; good compliance and willingness to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);\n3. Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);\n4. Patients who, in the judgment of the investigator, are not suitable for inclusion.",{"count":73,"type":20},504,"The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment",[25,76,77],"RWS","PD-1 Immunotherapy","2024-06-26",{"date":80,"type":31},"2024-07-03",{"date":82,"type":31},"2023-11-01",{"date":84,"type":20},"2026-10",{"name":37,"class":38},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":17,"enrollmentInfo":93,"targetDuration":4,"studyType":51,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":4},"100520873","protocol-for-comparing-the-efficacy-of-three-reconstruction-methods-of-the-digestive-tract-after-proximal-gastrectomy-100520873","NCT06062225","Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy","Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract (Kamikawa Versus Single-Tract Jejunal Interposition Versus SOFY Reconstruction) After Proximal Gastrectomy","Inclusion Criteria:\n\n* Age between 20-75 years old, male or female;\n* Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1\u002F3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) (14) according to the eighth edition of the AJCC (15);\n* No distant metastasis observed on preoperative chest radiograph, abdominal ultrasound or upper abdominal CT;\n* ASA grade 1-3;\n* Patients without contraindications to surgery;\n* Patients and their families voluntarily signing the informed consent form and participating in the study;\n\nExclusion Criteria:\n\n* Patients diagnosed with primary tumors or distant metastasis;\n* Patients whose tumor is located in the greater curvature side of the stomach;\n* Patients with coagulation dysfunction which could not be corrected;\n* Patients who were diagnosed with viral hepatitis and cirrhosis;\n* Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin;\n* Patients with organ failure such as heart, lung, liver, brain, kidney failure;\n* Patients with ascites or cachexia preoperatively in poor general conditions;\n* Patients diagnosed with immunodeficiency, immunosuppression or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).\n* Patients refusing to sign the informed consent of the study;",{"count":94,"type":20},180,[53],"The efficacy of three different reconstruction methods after proximal gastrectomy will be investigated in this study through a prospective, multicenter, randomized controlled trial.",[98,99,100,101,102],"Proximal Gastric Adenocarcinoma","Gastrectomy","Anastomosis","Reflux Esophagitis","Postoperative Complications","2023-10-03",{"date":105,"type":31},"2023-10-05",{"date":107,"type":20},"2023-10",{"date":84,"type":20},{"name":37,"class":38},""]